SI9111427B - Heterociklične spojine - Google Patents
Heterociklične spojine Download PDFInfo
- Publication number
- SI9111427B SI9111427B SI9111427A SI9111427A SI9111427B SI 9111427 B SI9111427 B SI 9111427B SI 9111427 A SI9111427 A SI 9111427A SI 9111427 A SI9111427 A SI 9111427A SI 9111427 B SI9111427 B SI 9111427B
- Authority
- SI
- Slovenia
- Prior art keywords
- group
- methoxy
- alkyl
- compound
- compounds according
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 14
- 125000000217 alkyl group Chemical group 0.000 claims abstract 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 3
- -1 1-methoxy-1-methylethyl Chemical group 0.000 claims 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims 2
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- LDCMOCGAIMMZPI-UHFFFAOYSA-N 2-methylundec-2-enoic acid Chemical compound CCCCCCCCC=C(C)C(O)=O LDCMOCGAIMMZPI-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000012374 esterification agent Substances 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-N phosphine group Chemical group P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heat Sensitive Colour Forming Recording (AREA)
Claims (12)
- Patentni zahtevki 1. Spojine s splošno formulo (I):označene s tem, da v formuli R; predstavlja skupino: — CH.O.C. (0 ) p. R 5 R4 0 kjer predstavlja vodik ali C; ^alkilno skupino; je p nič ali ena; R5 predstavlja skupino, ki je izbrana iz C; galkila, C5 ^cikloalkila, ki je v danem primeru substituiran s C; jalkilno skupino, fenila ali Cy^alkila, ki je substituiran s C; 5alkoksi skupino; in R2 predstavlja skupino OR5, kjer R^ predstavlja C; 5alkilno skupino.
- 2. Spojine po zahtevku 1, označene s tem, da imajo konfiguracijo: OH H(v kateri sta R; in R2 kot je definirano v zahtevku 1). • ec <* « · e r e 0 f • c <* * n e e λ r c *· r r r o r r r r r r r r c < 2
- 3. Spojine po zahtevku 1 ali zahtevku 2, označene s tem, da R4 predstavlja vodikov atom ali metilno skupino.
- 4. Spojine po kateremkoli od zahtevkov 1 do 3, označene s tem, da R2 predstavlja metoksi ali etoksi skupino.
- 5. Spojine po kateremkoli od zahtevkov 1 do 4, označene s tem, da R5 predstavlja metil, etil, izopropil, t-butil, 1-metoksi-l-metiletil, fenil, cikloheksil ali 4-etil-cikloheksilno skupino.
- 6. Spojine po zahtevku 2, označene s tem, da R^ predstavlja vodikov atom ali metilno skupino; je R5 skupina, ki je izbrana iz C/ 4alkila, C5 6cikloalkila, ki je v danem primeru substituiran s Cy 2alkilno skupino, fenila in Cy ^alkila, ki je substituiran z metoksi; in je R2 metoksi skupina.
- 7. Pivaloiloksimetil, 1-pivaloiloksietil, acetoksimetil, 1-acetoksietil, 1-metoksi-1-metiletilkarboniloksimetil, l-(l-metoksi-l-metiletilkarboniloksi)etil, 1-benzoil-oksietil, 1-izopropoksikarboniloksimetil in 1 - (4-etilcikloheksiloksikarboniloksi) -etiles tri (4S,8S,9R,10S,12R)-4-metoksi-10-(l-hidroksietil)-ll-okso-l-azatriciklo[7.2.0.03,s]u-ndec-2-en-2-karboksilne kisline.
- 8.1-cikloheksiloksikarboniloksietil (4S,8S,9R,10S,12R)-4-metoksi-10-(l-hidroksi-etil)-ll-okso-l-azatriciklo[7.2.0.0.i'5]undec-2-en-2-karboksilat.
- 9. Spojine po kateremkoli od zahtevkov 1 do 8 za uporabo v terapiji ali profilaksi sistemskih bakterijskih infekcij na organizmu ljudi in živali.
- 10. Uporaba spojine po kateremkoli od zahtevkov 1 do 8 v proizvodnji terapevtskega sredstva za zdravljenje ali profilakso sistemskih bakterijskih infekcij na organizmu ljudi ali živali.
- 11. Farmacevtski pripravki, označeni s tem, da obsegajo spojino po kateremkoli od zahtevkov 1 do 8 v zmesi z enim ali več fiziološko sprejemljivimi nosilci ali sestavinami. 0 * • · e r r r * «
- 12. Postopek za pripravo spojine s splošno formulo (I) po zahtevku 1, označen s tem, da obsega ali (a) reakcijo spojine s splošno formulo (II): 0 * • · e r r r * «v kateri je R2 kot je definirano v zahtevku 1 in Ra predstavlja atom vodika ali zaščitno skupino za hidroksil, ali njene soli ali njenega reaktivnega derivata s sredstvom za es-terifikacijo, ki služi za uvedbo skupine R;, kot je definirano v zahtevku 1, ali (b) cik-lizacijo spojine s splošno formulo (III):C 0 0 R (III) v kateri sta R; in R2 kot je definirano v zahtevku 1, je Rq zaščitna skupina za hidroksil in je Y atom kisika ali fosfinska skupina in nakar, če je potrebno ali če želimo, reakcijo produkta, da zamenjamo Rfl zaščitno skupino za hidroksil z atomom vodika in/ali ločitev določenega želenega izomera spojine s splošno formulo (I) od enega ali več njenih izomerov. Za GLAXO S.p.A.:
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB909018330A GB9018330D0 (en) | 1990-08-21 | 1990-08-21 | Heterocyclic compounds |
| GB919104770A GB9104770D0 (en) | 1991-03-07 | 1991-03-07 | Heterocyclic compounds |
| YU142791A YU48079B (sh) | 1990-08-21 | 1991-08-20 | Heterociklična jedinjenja |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SI9111427A SI9111427A (en) | 1996-12-31 |
| SI9111427B true SI9111427B (sl) | 2000-10-31 |
Family
ID=26297540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI9111427A SI9111427B (sl) | 1990-08-21 | 1991-08-20 | Heterociklične spojine |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US5587374A (sl) |
| EP (1) | EP0495953B1 (sl) |
| JP (2) | JP3151215B2 (sl) |
| KR (1) | KR0169147B1 (sl) |
| CN (1) | CN1030917C (sl) |
| AP (1) | AP238A (sl) |
| AT (1) | ATE106887T1 (sl) |
| AU (1) | AU647178B2 (sl) |
| CA (1) | CA2067741C (sl) |
| CY (1) | CY2037A (sl) |
| CZ (1) | CZ280942B6 (sl) |
| DE (1) | DE69102415T2 (sl) |
| DK (1) | DK0495953T3 (sl) |
| ES (1) | ES2054502T3 (sl) |
| FI (1) | FI97136C (sl) |
| HK (1) | HK19495A (sl) |
| HR (1) | HRP940556B1 (sl) |
| HU (2) | HUT61024A (sl) |
| IE (1) | IE66122B1 (sl) |
| IL (1) | IL99248A (sl) |
| MX (1) | MX9100743A (sl) |
| MY (1) | MY106997A (sl) |
| NO (1) | NO300176B1 (sl) |
| NZ (1) | NZ239474A (sl) |
| OA (1) | OA09578A (sl) |
| PL (1) | PL169425B1 (sl) |
| PT (1) | PT98729B (sl) |
| SG (1) | SG169494G (sl) |
| SI (1) | SI9111427B (sl) |
| SK (1) | SK278470B6 (sl) |
| WO (1) | WO1992003437A1 (sl) |
| YU (1) | YU48079B (sl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9104838D0 (en) * | 1991-03-07 | 1991-04-17 | Glaxo Spa | Heterocyclic compounds |
| AP294A (en) * | 1992-08-31 | 1993-12-28 | Glaxo Spa | "10-(1-Hydroxyethyl)-11-oxo-1-azatricyclo-(7.2.0.0.3.8) undec-2-ene-2-carboxylic acid derivatives". |
| GB9218781D0 (en) * | 1992-09-04 | 1992-10-21 | Glaxo Spa | Heterocyclic derivatives |
| IN188720B (sl) * | 1997-11-06 | 2002-11-02 | Panacea Biotec Ltd | |
| CA2465336C (en) | 2001-11-05 | 2009-04-28 | Sumitomo Pharmaceuticals Co., Ltd. | Novel carbapenem compounds |
| JPWO2004089954A1 (ja) * | 2003-04-08 | 2006-07-06 | 大日本住友製薬株式会社 | 新規なカルバペネム化合物 |
| WO2006025475A1 (ja) * | 2004-09-03 | 2006-03-09 | Dainippon Sumitomo Pharma Co., Ltd. | 新規なカルバペネム化合物 |
| US20090029964A1 (en) * | 2005-03-25 | 2009-01-29 | Makoto Sunagawa | Novel carbapenem compound |
| EP2085084A1 (en) * | 2008-01-29 | 2009-08-05 | LEK Pharmaceuticals D.D. | Use of inhibitor of beta-lactamases and its combination with beta-lactam antibiotics |
| EP2135871A1 (en) * | 2008-06-18 | 2009-12-23 | LEK Pharmaceuticals D.D. | New trinem antibiotics and inhibitors of beta-lactamases |
| PL3621609T3 (pl) | 2017-05-08 | 2022-11-14 | Glaxosmithkline Intellectual Property Development Limited | Sanfetrinem lub jego sól lub ester do stosowania w leczeniu zakażenia prątkami |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1425571A (en) * | 1972-03-13 | 1976-02-18 | Astra Laekemedel Ab | Penicillins and cephaosporins |
| GB1433131A (en) * | 1972-03-13 | 1976-04-22 | Astra Laekemedel Ab | Penicillins |
| DE2811514A1 (de) * | 1977-03-19 | 1978-09-21 | Beecham Group Ltd | Ester der 7-oxo-1-azabicyclo eckige klammer auf 3.2.0 eckige klammer zu hept- 2-en-2-carbonsaeure und deren derivate, verfahren zur herstellung dieser verbindungen und diese verbindungen enthaltende pharmazeutische zubereitungen |
| US4374849A (en) * | 1981-09-14 | 1983-02-22 | Merck & Co., Inc. | 6-Amidocyclonocardicins |
| US4374848A (en) * | 1981-09-14 | 1983-02-22 | Merck & Co., Inc. | 6-(1-Hydroxyethyl)cyclonocardicin |
| CZ285778B6 (cs) * | 1989-09-08 | 1999-11-17 | Glaxo S.P.A. | Kyselina 10-(1-hydroxyethyl)-11-oxo-1-azatricyklo/7,2,0,03,8/-undec-2en-2-karboxylová a její deriváty, způsob jejich výroby, použití pro výrobu farmaceutických prostředků a farmaceutické prostředky s jejich obsahem |
| AU636913B2 (en) * | 1989-10-11 | 1993-05-13 | Takeda Chemical Industries Ltd. | Tricyclic carbapenem compounds |
| GB9104832D0 (en) * | 1991-03-07 | 1991-04-17 | Glaxo Spa | Heterocyclic compounds |
| GB9104838D0 (en) * | 1991-03-07 | 1991-04-17 | Glaxo Spa | Heterocyclic compounds |
-
1991
- 1991-08-20 CA CA002067741A patent/CA2067741C/en not_active Expired - Fee Related
- 1991-08-20 DK DK91914351.1T patent/DK0495953T3/da active
- 1991-08-20 SI SI9111427A patent/SI9111427B/sl unknown
- 1991-08-20 CZ CS921213A patent/CZ280942B6/cs not_active IP Right Cessation
- 1991-08-20 PL PL91294573A patent/PL169425B1/pl unknown
- 1991-08-20 AT AT91914351T patent/ATE106887T1/de not_active IP Right Cessation
- 1991-08-20 ES ES91914351T patent/ES2054502T3/es not_active Expired - Lifetime
- 1991-08-20 HU HU921303A patent/HUT61024A/hu unknown
- 1991-08-20 CN CN91109093A patent/CN1030917C/zh not_active Expired - Fee Related
- 1991-08-20 WO PCT/EP1991/001589 patent/WO1992003437A1/en not_active Ceased
- 1991-08-20 MX MX9100743A patent/MX9100743A/es unknown
- 1991-08-20 DE DE69102415T patent/DE69102415T2/de not_active Expired - Fee Related
- 1991-08-20 NZ NZ239474A patent/NZ239474A/en unknown
- 1991-08-20 MY MYPI91001514A patent/MY106997A/en unknown
- 1991-08-20 YU YU142791A patent/YU48079B/sh unknown
- 1991-08-20 AP APAP/P/1991/000320A patent/AP238A/en active
- 1991-08-20 IL IL9924891A patent/IL99248A/en not_active IP Right Cessation
- 1991-08-20 EP EP91914351A patent/EP0495953B1/en not_active Expired - Lifetime
- 1991-08-20 IE IE294491A patent/IE66122B1/en not_active IP Right Cessation
- 1991-08-20 JP JP51366091A patent/JP3151215B2/ja not_active Expired - Fee Related
- 1991-08-20 SK SK1213-92A patent/SK278470B6/sk unknown
- 1991-08-20 PT PT98729A patent/PT98729B/pt not_active IP Right Cessation
- 1991-08-20 AU AU84212/91A patent/AU647178B2/en not_active Ceased
-
1992
- 1992-04-13 OA OA60190A patent/OA09578A/en unknown
- 1992-04-15 NO NO921521A patent/NO300176B1/no unknown
- 1992-04-16 FI FI921717A patent/FI97136C/fi active
- 1992-04-20 KR KR1019920700916A patent/KR0169147B1/ko not_active Expired - Fee Related
-
1994
- 1994-09-16 HR HR940556A patent/HRP940556B1/xx not_active IP Right Cessation
- 1994-12-01 SG SG169494A patent/SG169494G/en unknown
-
1995
- 1995-02-09 HK HK19495A patent/HK19495A/en not_active IP Right Cessation
- 1995-02-14 US US08/388,515 patent/US5587374A/en not_active Expired - Fee Related
- 1995-06-27 HU HU95P/P00455P patent/HU211584A9/hu unknown
-
1998
- 1998-02-20 CY CY203798A patent/CY2037A/xx unknown
-
2000
- 2000-05-17 JP JP2000144232A patent/JP3461786B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69332220T2 (de) | Lösliche analoga von probucol | |
| DE3005164C2 (de) | 1,1-Dioxopenicillanoyloxymethyl-6-(D-&alpha;-amino-&alpha;-phenylacetamido)-penicillanat, Verfahren zu seiner Herstellung und es enthaltendes Arzneimittel | |
| Nudelman et al. | Novel anticancer prodrugs of butyric acid. 2 | |
| EP0038192B2 (en) | 5-Alkylsalicylanilides derivatives and method for inhibiting the growth of microorganisms | |
| AU8531101A (en) | Immunoregulatory compounds and derivatives and methods of treating diseases therewith | |
| SI9111427B (sl) | Heterociklične spojine | |
| WO1999026632B1 (en) | Phospholipids having antimicrobial activity with or without the presence of antimicrobials | |
| EP0049593B1 (en) | 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline carboxylic acid and metal salts thereof useful in burn therapy | |
| KR20070026839A (ko) | 신규한 용도 | |
| WO2008035243A2 (en) | Composition for treatment of burns and wounds | |
| ATE22078T1 (de) | 1-ethyl-6,8-difluor-1,4-dihydro-7-(1-imidazolyl - 4-oxochinolincarbonsaeurederivate, verfahren zu ihrer herstellung und antibakterielle zusammensetzungen. | |
| CA2386685A1 (en) | Use of pleuromutilin derivatives for transdermal treatment of bacterial diseases | |
| CA2183486A1 (en) | Prostaglandin derivatives | |
| US4522819A (en) | 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline carboxylic acid and metal salts thereof useful in burn therapy | |
| EP0128338A1 (en) | Silver pseudomonate, compositions containing it and its use in treating pseudomonal infections | |
| US5679711A (en) | Hydroxyl ions as novel therapeutic agents and compounds that modulate these ions, compositions employing these agents, therapeutic methods for using such agents | |
| US5391558A (en) | Composition for accelerating healing of wound | |
| EP0439450B1 (en) | Pharmaceutical composition | |
| FI67856B (fi) | Foerfarande foer framstaellning av ett antibakteriellt silversalt av fosfanilsyra | |
| JPH06505259A (ja) | 複素環式化合物 | |
| DE69702158T2 (de) | Carnitine-Bisalkanoylester mit bakterizider, fungizider und antiprotozoischer Wirkung | |
| JPS61191685A (ja) | アルキレンヘテロ原子架橋により結合せしめられた２位置換基を有するカルバペネム類 | |
| CN119326725B (zh) | 注射用厄他培南钠的制备方法 | |
| EP0498243B1 (en) | Fosfomycin cetyltrimethylammonium salt and composition containing it, for the topical treatment of vaginal and urethral infections | |
| IE892257A1 (en) | Anti-infective agent, process for its preparation and its¹use in therapy |